Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialGlobeNewsWire • 05/05/26
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD StrengthZacks Investment Research • 04/29/26
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 04/29/26
Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter DrugInvestors Business Daily • 04/29/26
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?Zacks Investment Research • 04/27/26
Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing lossCNBC • 04/24/26
Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 04/24/26
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.GlobeNewsWire • 04/23/26
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for freeCNBC • 04/23/26
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in UrticariaZacks Investment Research • 04/23/26
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.GlobeNewsWire • 04/23/26